Macrophage inflammatory protein-1β (MIP-1β) is a member of the CC chemokine family. MIP-1β directly impaired human endothelial progenitor cell (EPC) function. Inhibition of MIP-1β could improve the EPC function of normal subjectstype 2 diabetic patients,enhance in vivo EPC homingischemia-induced neovasculogenesis in type 1type 2 diabetic animals.

Type 2 diabetic patients with severe peripheral arterial disease often suffered from lower limb amputationeven death. Inhibition on MIP-1β is a novel strategy to effectively enhance endothelial progenitor cells from type 2 diabetic patients,improve lower limb ischemiarestore blood flow in diabetic animals. It may be a new treatment for diabetic peripheral arterial disease.

Of the world＇s type 2 diabetic people, 15 (about 56,000,000 to 86,700,000) are associated with severe peripheral arterial diseasediabetic foot. There are 5 new diabetic feet1 with amputationeven death each year. This new technology will potentially prevent the progress of diabetic footreduce amputation in patients with type 2 diabetes with severe peripheral arterial disease.